Bristol-Myers Squibb Company

Senior Translational Research Investigator - Liquid Biopsy

Cambridge, MA, US
Jan 22, 2019
Required Education
Position Type
Full time
Bristol-Myers Squibb R&D is a science-driven, passionate organization determined to discover, develop and deliver medicines that have the potential to transform the lives of patients and establish new standards of care in areas of high unmet need. Patients' needs and scientific discovery are our driving force. The new Bristol-Myers Squibb research site in Cambridge's Kendall Square will position our scientific team in the heart of a vibrant ecosystem of world-class science, innovation and business opportunities. Our scientists will focus on novel targets and pathways for tumors that are refractory to current Immuno-Oncology therapies. These are significant challenges that will require innovative solutions from the biopharma, biotech and academic communities.

Role / Responsibilities

We are seeking an experienced scientist to join our Translational Research group in our new state-of-the-art facility. The qualified candidate is a highly motivated, interactive, and creative individual who possesses the ability to work across a highly matrixed environment to advance translational research efforts. The candidate will be expected to develop liquid biopsy strategies to address response and resistance to checkpoint immunotherapies. To be successful in this role, the candidate must effectively collaborate with colleagues in the oncology, immunology and immuno-oncology groups, as well as liaise with the wider translational medicine, discovery and clinical teams. The candidate should be well-versed liquid biopsy assay development and biomarker strategies, with a strong track record of achievement in the field, including the development of novel biomarkers using of cutting-edge analytical approaches. The ideal candidate should be proficient in one or more technical approaches in the blood biomarker space, including flow cytometry, metabolomics, gene expression analysis, and exosome identification and characterization. To be at the forefront of elucidating and overcoming resistance to IO therapies, we encourage scientists who are passionate problem solvers that thrive on clinically-vital challenges, to consider this opportunity.

Qualifications / Essential Skills
  • PhD in Cancer Biology or Immunology, or equivalent advanced biology degree
  • Experienced scientist with 5-10+ years' of post-graduate research experience, with a minimum of 3 years in a translational setting
  • Minimum 3+ years' recent experience in leading scientific teams in an academic or industry setting
  • Hands-on experience in biomarker development and working with blood and blood products
  • Proficient in a combination of analytical approaches, including flow cytometry, metabolomics, gene expression analysis, secretion profiling, and/or exosome identification and characterization
  • Track record of developing novel biomarkers and adopting new technologies to advance the field
  • Knowledge of biomarker clinical strategy and the immune oncology biomarker landscape
  • Experience in balanced experimental design, data visualization and basic statistical analysis are desirable
  • A track record of independent critical thinking and scientific achievement demonstrated by first authorship in recent high impact publications
  • Expertise in cancer immunotherapy including immune-checkpoint blockade with knowledge of current therapeutic landscape is highly desirable
  • Prior role in multidisciplinary projects and teams with ability to integrate cross-functional information, desired but not required
  • Experience with managing CRO relationships and collaborating with KOL's would be advantageous
  • Excellent interpersonal skills and ability to communicate, both written and oral effectively and efficiently within the BMS organization and with external partners/collaborators
  • Seeking an individual who will thrive in a fast-paced, dynamic work environment, who brings a pro-active mentality to the role

We follow the science and we'll continue to invest in translational medicine research, deepen our understanding of disease biology and uncover insights about predictive biomarkers, with the ultimate goal of making precision medicine a reality for more patients.